iShares Nasdaq Biotechnology ETF (IBB)
107.59
+0.25 +0.23%
NASDAQ
May 25, 16:48
Delayed 2m
USD
IBB Key Stats
| Net Asset Value | Upgrade |
| Discount or Premium to NAV | Upgrade |
| Turnover Ratio | Upgrade |
View All IBB News
IBB News
-
WireHeadlineTime (ET)
-
MT Newswires05/25 13:33
-
MT Newswires05/25 09:20
-
MT Newswires05/24 13:37
-
MT Newswires05/24 09:23
-
MT Newswires05/23 13:34
-
MT Newswires05/23 09:27
-
MT Newswires05/22 13:41
-
MT Newswires05/22 09:22
-
SA Breaking News05/21 15:42
-
Yahoo05/21 14:00
IBB Performance
| Total Return (Price) | Total Return (NAV) | Cat. Total Return (NAV) | % Rank in Cat. (NAV) | |
|---|---|---|---|---|
| 1M | 3.94% | 3.93% | 3.93% | 71 |
| 3M | -3.02% | -3.10% | 1.25% | 91 |
| 6M | 3.25% | 3.21% | 8.63% | 84 |
| YTD | 0.53% | 0.52% | 6.46% | 88 |
| 1Y | 10.96% | 10.95% | 18.11% | 67 |
| 3Y | -3.84% | -3.84% | 3.61% | 95 |
| 5Y | 12.44% | 12.42% | 13.76% | 60 |
| 10Y | 15.61% | 15.62% | 13.38% | 23 |
IBB Asset Allocation
| Type | % Net | % Long | % Short |
|---|---|---|---|
| Cash | 0.08% | 0.08% | 0.00% |
| Stock | 99.92% | 99.92% | 0.00% |
| Bond | 0.00% | 0.00% | 0.00% |
| Convertible | 0.00% | 0.00% | 0.00% |
| Preferred | 0.00% | 0.00% | 0.00% |
| Other | 0.00% | 0.00% | 0.00% |
IBB Region Exposure
| Americas | 97.14% |
| North America | 97.14% |
| Latin America | 0.00% |
| Greater Europe | 2.49% |
| United Kingdom | 0.78% |
| Europe Developed | 1.68% |
| Europe Emerging | 0.00% |
| Africa/Middle East | 0.03% |
| Greater Asia | 0.37% |
| Japan | 0.00% |
| Australasia | 0.00% |
| Asia Developed | 0.00% |
| Asia Emerging | 0.37% |
| Market Classification | |
| % Developed Markets | 99.63% |
| % Emerging Markets | 0.37% |
IBB Stock Sector Exposure
| Basic Materials | 0.00% |
| Communication Services | 0.00% |
| Consumer Cyclical | 0.00% |
| Consumer Defensive | 0.06% |
| Energy | 0.00% |
| Financial Services | 0.00% |
| Healthcare | 99.88% |
| Industrials | 0.00% |
| Real Estate | 0.00% |
| Technology | 0.05% |
| Utilities | 0.00% |
IBB Stock Market Capitalization
| Giant | 14.89% |
| Large | 37.58% |
| Medium | 24.48% |
| Small | 19.32% |
| Micro | 3.73% |
IBB Stock Style Exposure
| Large Cap Value | 20.35% |
| Large Cap Blend | 8.24% |
| Large Cap Growth | 26.36% |
| Mid Cap Value | 0.00% |
| Mid Cap Blend | 2.76% |
| Mid Cap Growth | 21.26% |
| Small Cap Value | 1.31% |
| Small Cap Blend | 6.55% |
| Small Cap Growth | 13.15% |
View More Holdings
As of May 22, 2018
IBB Top 10 Holdings
| Symbol | Name | % Weight | Price | % Chg |
|---|---|---|---|---|
| AMGN | Amgen Inc | 7.87% | 178.24 | +0.16% |
| BIIB | Biogen Inc | 7.85% | 286.09 | +0.59% |
| CELG | Celgene Corp | 7.13% | 78.70 | -1.06% |
| GILD | Gilead Sciences Inc | 6.99% | 67.33 | -0.30% |
| VRTX | Vertex Pharmaceuticals Inc | 5.36% | 157.52 | +0.35% |
| ILMN | Illumina Inc | 4.82% | 266.26 | -1.69% |
| REGN | Regeneron Pharmaceuticals Inc | 3.73% | 293.73 | -0.30% |
| ALXN | Alexion Pharmaceuticals Inc | 3.63% | 117.72 | +0.50% |
| MYL | Mylan NV | 2.89% | 39.37 | +0.10% |
| BMRN | Biomarin Pharmaceutical Inc | 2.12% | 92.48 | +4.76% |
Advertisement
IBB One Page Reports
- One Page Report Download
IBB Basic Info
| Style | |
|---|---|
| Equity Style | Mid Cap/Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | iShares |
| Benchmark Index | |
|---|---|
NASDAQ Biotechnology TR USD |
100.0% |
IBB Manager Info
| Name | Tenure |
|---|---|
| Alan Mason | 2.04 yrs |
| Diane Hsiung | 10.34 yrs |
| Greg Savage | 10.34 yrs |
| Jennifer Hsui | 5.75 yrs |
IBB Net Fund Flows
| 1M | -230.59M |
| 3M | -980.83M |
| 6M | -1.007B |
| YTD | -1.164B |
| 1Y | -77.20M |
| 3Y | 1.003B |
| 5Y | 2.930B |
| 10Y | 3.271B |
IBB Risk Info
| Beta (5Y) | 1.288 |
| Max Drawdown (All) | 62.85% |
| Historical Sharpe (10Y) | 0.7997 |
| Historical Sortino (All) | 0.5576 |
| 30-Day Rolling Volatility | 17.90% |
| Daily Value at Risk (VaR) 1% (All) | 4.84% |
| Monthly Value at Risk (VaR) 1% (All) | 19.54% |
IBB Fundamentals
| Dividend Yield TTM (5-25-18) | 0.42% |
| SEC Yield (4-30-18) | 0.13% |
| Weighted Average PE Ratio | 28.30 |
| Weighted Average Price to Sales Ratio | 6.084 |
| Weighted Average Price to Book Ratio | 4.995 |
| Weighted Median ROE | 1.28% |
| Weighted Median ROA | -6.65% |
| Forecasted Dividend Yield | 0.54% |
| Forecasted PE Ratio | 15.04 |
| Forecasted Price to Sales Ratio | 4.838 |
| Forecasted Price to Book Ratio | 3.522 |
| Number of Holdings | 194 |
IBB Growth Estimates
| Forecasted 5 Yr Earnings Growth | 13.80% |
| Forecasted Book Value Growth | 13.64% |
| Forecasted Cash Flow Growth | 4.23% |
| Forecasted Earnings Growth | -11.84% |
| Forecasted Revenue Growth | 11.21% |
IBB Attributes
| Key Dates | |
|---|---|
| Inception Date | 2/5/2001 |
| Termination Date | |
| Last Annual Report Date | 3/31/2017 |
| Last Prospectus Date | 12/1/2017 |
| Attributes | |
| Exchange Traded Share | Yes |
| Exchange Traded Note | No |
| Enhanced Index Fund | No |
| Index Fund | Yes |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | Yes |
| General Availability | |
| Available for Insurance Product | No |
| Available for Retirement Plan | No |
| Available for RRSP | No |
IBB Excel Add-In Codes
- Name: =YCI("IBB","name")
- Broad Asset Class: =YCI("IBB", "broad_asset_class")
- Broad Category: =YCI("IBB", "broad_category_group")
- Prospectus Objective: =YCI("IBB", "prospectus_objective")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Advertisement
